O veractive renin-angiotensin system and chronically elevated angiotensin II (Ang-II) levels are widely recognized as major factors in the development and maintenance of hypertension. The renin-angiotensin system comprises renin, which metabolizes angiotensinogen to the decapeptide Ang-I, which is further cleaved by angiotensin-converting enzyme (ACE) to the octapeptide Ang-II. ACE2, an ACE homologue insensitive to ACE inhibitors, was identified in 2000. 1 ACE2 acts primarily on Ang-II to generate the vasodilatory heptapeptide Ang-(1-7). The effects of Ang-II and Ang-(1-7) are mediated by interactions with specific plasma membrane receptors, that is, Ang-II type 1 receptor (AT 1 ), AT 2 , and Mas, all of which are G-protein-coupled receptors. AT 1 receptor (AT 1 R) activation by Ang-II leads to elevated blood pressure (BP), hypertrophy, and fibrosis, whereas Mas receptor (MasR) activation by Ang-(1-7) results in effects opposite to AT 1 R activation, such as vasodilation, growth inhibition, and antifibrotic actions. 2 Thus, the ACE2/Ang-(1-7)/MasR axis provides emerging therapeutic targets to prevent the pathological actions of Ang-II.
are partly characterized, 10 almost nothing is known about how chronic elevated Ang-II levels modulate the expression, subcellular localization, and activity of other renin-angiotensin system members with plasma membrane localization, such as ACE and ACE2.
ACE mRNA was found to be markedly upregulated while ACE2 mRNA downregulated in hypertensive patients. 11 This transcriptional regulation was also observed in vitro in kidney tubular epithelial cells after Ang-II treatment and could be prevented through inhibition of MAP kinases. ACE and ACE2 are type I membrane proteins with a single-pass N-terminus domain, a short transmembrane domain, and a short C-terminus. Other members of the metallopeptidase family, such as β-site APP-cleaving enzyme, were extensively shown in pathological conditions to internalize into early endosomes and undergo ubiquitination followed by lysosomal degradation, contributing to the progression of Alzheimer disease. 12, 13 ACE2 has been also identified as the cellular receptor for the severe acute respiratory syndrome coronavirus (SARS-CoV). 14, 15 Interestingly, ACE2 expression is reduced after SARS-CoV infection, suggesting a regulated internalization mechanism. The route of internalization of the ACE2/SARS-CoV complex remains under debate, with reports of clathrin-and caveolaeindependent pathways in HEK293T cells as well as clathrindependent and C-terminus-independent internalization in COS7 and HepG2 cell lines. 16, 17 In addition, ACE2 polymorphisms have been associated with hypertension in humans. Despite an increase in ACE2 mRNA and protein expression in the early phase of several cardiovascular diseases, seen as a compensatory mechanism, the expression of the carboxypeptidase is usually reduced in later phases of disease progression. Interestingly, this latter decrease can be prevented or reversed by ACE inhibitors or AT 1 R blockers. Although these data suggest that the ACE/ Ang-II/AT 1 R axis is responsible for downregulation of ACE2, the mechanisms involved remain unknown. Therefore, the goal of the present study was to investigate the effects of Ang-II on ACE2 cellular levels, localization, and activity and to define the cellular mechanisms associated with these effects.
Methods
An expanded Materials and Methods section is available in the online-only Data Supplement.
Cell Culture and Transfection
Neuro-2A and HEK293T cells (ATCC) were cultured in Dulbecco modified Eagle medium with 10% fetal bovine serum, 10 U/mL penicillin, and 100 μg/mL streptomycin. The cells were transiently transfected using Lipofectamine 2000 reagent (Invitrogen) in Dulbecco modified Eagle medium with no antibiotics and fetal bovine serum at ≈80% confluence according to manufacturer's instructions. After 6 hours, the cells were trypsinized and plated at the desired density in full medium for the next 30 hours. The cells were serum-starved 24 hours before each experiment.
BP Recordings
Experiments were performed in adult (14-16 weeks old; 25-30 g) male C57Bl/6 (Jackson Laboratories) and ACE2 knockout (ACE2 −/y ) mice (kind gift of Drs Thomas M. Coffman and Susan B. Gurley, Duke University). Animals were housed in a temperature-and humidity-controlled facility under a 12-hour dark/light cycle and fed standard mouse chow and water ad libitum. All procedures were approved by the LSU Health Sciences Center-NO Animal Care and Use Committee and are in agreement with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Baseline BP was measured in ACE2 −/y and nontransgenic mice during 3 days using radiotelemetry, as described. 5 Mice were infused subcutaneously with Ang-II (600 ng/kg per minute) or vehicle (0.9% saline) for 14 days using osmotic pumps (Alzet). After anesthesia with isoflurane, as above, mice were additionally implanted with an intracerebroventricular cannula connected to a subcutaneous osmotic pump containing leupeptin (460 ng/kg per minute) or artificial cerebrospinal fluid. BP was continually recorded for 17 days.
Statistics
Data are presented as mean±SEM. Data were analyzed by repeatedmeasures ANOVA or 2-way ANOVA, followed by Bonferroni posttests, as appropriate. Statistical comparisons were performed using Prism 5 (GraphPad Software). Differences were considered statistically significant at P<0.05.
Results

Ang-II Decreases ACE2 Protein Expression and Activity in Neurons
Neuro-2A cells, a murine neuroblastoma cell line, have been previously used by our group and others to study oxidative stress and ACE2 expression in response to endogenous AT 1 R stimulation. 7 Because these cells express low levels of ACE2, activity is beyond detectable levels in nontransfected Neuro-2A cells. To study ACE2 subcellular localization, Neuro-2A cells were transfected with an ACE2-GFP fusion plasmid allowing for fluorescent detection and quantification of the enzyme in various subcellular compartments. Ang-II treatment markedly decreased ACE2 activity as early as 4 hours, and this effect was prevented by pretreatment with losartan ( Figure 1A ), suggesting that this inhibition is mediated by AT 1 R. Surprisingly, this decrease was also eliminated by treatment with the protease inhibitor, leupeptin ( Figure 1A ). The effects of leupeptin suggest that Ang-II-mediated ACE2 internalization may lead to lysosomal degradation.
Because we recently reported that ACE2 undergoes shedding from the plasma membrane in neurogenic hypertension, 5 activity of the enzyme was assessed in the cell medium. In these conditions, ACE2 activity was minimal in the medium (9±2% of the total activity) and this was not changed by Ang-II treatment, indicating that shedding was not responsible for the decreased ACE2 activity.
To test whether this reduction was because of changes in subcellular localization, we next investigated the effects of Ang-II on the plasma membrane levels of ACE2. To this end, we used biotinylation, a procedure that labels exclusively plasma membrane proteins. In agreement with the above observations, by 4 hours, Ang-II treatment had clearly decreased (≈50%) the amount of ACE2 present at the plasma membrane with no further reduction at 18-hour post-treatment ( Figure 1B) . Interestingly, the total cellular ACE2 levels determined by Western blot were significantly decreased after 18 hours ( Figure 1C ) but not after 4 hours of Ang-II treatment, supporting the hypothesis that Ang-II promotes ACE2 internalization followed by degradation.
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In untreated Neuro-2A cells, ACE2 displays a predominant cell surface localization as indicated by colocalization with wheat germ agglutinin, a specific plasma membrane marker ( Figure 2A ). However, after 4-hour Ang-II treatment, ACE2 was barely detectable at the plasma membrane and had clearly accumulated within the cytoplasm, confirming internalization of the carboxypeptidase. Further investigation revealed that ACE2 accumulates into lysosomes after Ang-II treatment, as shown by colocalization with Rab7-positive Neuro-2A cells ( Figure 2B ). To further investigate the contribution of AT 1 R in ACE2 internalization, we repeated these experiments in HEK293T cells, which lack endogenous expression of this receptor. 18 In contrast to Neuro-2A cells, ACE2 plasma membrane localization was not changed by treatment with Ang-II in HEK293T cells ( Figure 3A ), suggesting that AT 1 R is required for ACE2 internalization. Indeed, transfection of AT 1 R to these cells prompted Ang-II-mediated ACE2 internalization ( Figure 3B ). In addition, this observation was specific for AT 1 R, because ACE2 was in proximity but not clearly colocalized with AT 2 R or MasR in HEK293T cells ( Figure 4A ). Furthermore, ACE2 activity was not changed in cells cotransfected with AT 2 R or MasR, but was clearly inhibited in HEK293T cells transfected with AT 1 R after Ang-II treatment ( Figure 4B ). As in Neuro-2A cells, these effects were eliminated by pretreatment with losartan or leupeptin ( Figure 4B ).
ACE2 Internalization Involves Ubiquitination and AT 1 R Interaction
Because ubiquitination is the major post-translational modification responsible for lysosomal targeting of plasma membrane proteins 19 and Ang-II treatment targets ACE2 to lysosomes ( Figure 2B ), we next investigated ACE2 ubiquitination levels in transfected HEK293T cells. In basal conditions, ACE2 displayed small levels of ubiquitination irrespective of AT 1 R presence, and Ang-II clearly enhanced ACE2 ubiquitination after 1-hour post-treatment ( Figure 5A ).
Because AT 1 R seems to be essential for Ang-II-mediated ACE2 internalization, we also tested whether ACE2 and AT 1 R physically interact. Coimmunoprecipitation experiments confirmed this dimerization in control conditions (Figure 5B 
Leupeptin Restores ACE2 Activity and Prevents the Development of Ang-II-Dependent Hypertension
Based on our findings at the cellular level, we next assessed whether ACE2 internalization may contribute to the development of Ang-II-induced hypertension in vivo. Using the slow-pressor dose model, 6 chronic infusion of Ang-II led to a progressive increase in BP in C57Bl/6 mice that peaked to ≈140 mm Hg after 2 weeks ( Figure 6A and 6C) . Although chronic central infusion of leupeptin alone (460 ng/h for 2 weeks) did not have a significant effect on BP, coadministration of Ang-II subcutaneous and leupeptin intracerebroventricular resulted in a significant blunting of the BP increase ( Figure 6A and 6C). To address the contribution of ACE2 to this observation, ACE2 −/y were similarly infused with Ang-II and leupeptin. Interestingly, although the Ang-II pressor response was similar in nontransgenic and ACE2 −/y , leupeptin was not able to inhibit the Ang-II-induced hypertension in ACE2 −/y mice ( Figure 6B and 6C). These data indicate that leupeptin beneficial effects are, at least in part, mediated by preservation of ACE2 activity in the presence of elevated Ang-II levels. This conclusion is supported by measurements of ACE2 activity in the hypothalami of these mice. Indeed, Ang-II infusion resulted in a clear reduction of hypothalamic ACE2 activity that could be restored after coadministration of leupeptin ( Figure 6D ).
Discussion
The primary goal of the present study was to clarify the mechanisms involved in the reduction of ACE2 compensatory properties during the development of Ang-II-mediated hypertension. We observed that ACE2 is internalized on Ang-II treatment, leading to a reduction of its enzymatic activity on the cell surface. Within the cytoplasm, ACE2 colocalizes with lysosomes where it undergoes degradation, a process involving ubiquitination, further reducing ACE2 activity within the cell. Internalization and degradation of ACE2 were inhibited by the AT 1 R blocker losartan and the protease inhibitor leupeptin. In addition, leupeptin infusion in the brain blunted the development of Ang-II-mediated hypertension in C57Bl/6 mice, confirming that ACE2 degradation contributes to neurogenic hypertension. To our knowledge, our data provide the first demonstration that elevated Ang-II levels decrease ACE2 activity through an AT 1 R-dependent internalization mechanism followed by lysosomal targeting for degradation.
Human ACE2 has 805 amino acids, organized in a short cytoplasmic domain (44 amino acids), a transmembrane helix (21 amino acids), and a very long extracellular domain containing a single catalytic metallopeptidase unit responsible for the cleavage of Ang-II into Ang-(1-7). Limitation of Ang-II levels by ACE2 has been shown to have multiple positive effects in various cardiovascular pathological models, 4, 8, [20] [21] [22] [23] [24] [25] [26] [27] [28] including Ang-II-induced neurogenic hypertension. 3, [5] [6] [7] 29 However, as the disease progresses, ACE2 compensatory mechanisms fail, as evidenced by reduction in protein expression and activity. 3, 8, 28 Several mechanisms have been proposed for ACE2 downregulation. A reduction of ACE2 mRNA in astrocytes after Ang-II treatment was previously reported, 30 and similar observations were made in kidneys isolated from Goldblatt hypertensive rats 31 and brains from chronic heart failure rabbits, 32 2 models with elevated systemic Ang-II levels, suggesting that Ang-II can modulate the transcriptional regulation of ACE2. In addition, a recent study demonstrated that Ang-II treatment leads to a reduction in ACE2 mRNA and protein levels in catecholaminergic neurons, an effect that was prevented by p38 and MAP kinase inhibitors, 33 confirming that these signaling mechanisms are involved in ACE2 gene expression. Post-transcriptional mechanisms have also been suggested, in particular during exercise training where expression of ACE2 was correlated with a reduction of microRNA 143 in the heart. 34 Although some steps have been taken to understand ACE2 transcriptional regulation in vivo, there is very limited knowledge regarding the enzyme's post-translational regulation. ACE2 shedding was shown to contribute to the enzyme cell surface activity, through an ADAM17-dependent mechanism. 35, 36 Consequently, ADAM17 has been speculated to contribute to the cleavage and release of the extracellular domain of ACE2 in plasma 37 and urine. 38, 39 Recently, our group demonstrated that ACE2 shedding takes place in neurogenic hypertension and can be reversed by inhibition of ADAM17 in the CNS. 5 In contrast, and despite our early observations that ACE2 expression can be localized to the cytoplasm of neurons, 40 the effects of Ang-II on ACE2 plasma membrane localization and internalization have not been investigated. This lack of information is surprising considering that ACE2 is also a cellular receptor for SARS-CoV and that ACE2 expression and plasma membrane levels are reduced after SARS-CoV infection, indicating a regulated internalization mechanism. 41, 42 Similarly, other members of the metallopeptidase family, such as β-site APP-cleaving enzyme, were extensively shown in pathological conditions to internalize into early endosomes and undergo ubiquitination followed by lysosomal degradation. 15, 43 In the present study, we observed that in Neuro-2A cells, ACE2 activity is markedly reduced by Ang-II and this effect is completely blocked by leupeptin, an inhibitor of the proteases found in lysosomes, indicating that elevated Ang-II levels target ACE2 for degradation. In agreement with this conclusion, ACE2 was shown to be colocalized with Rab7, a well-characterized lysosomal marker. In addition, Ang-II treatment enhanced ACE2 ubiquitination, a post-translational modification essential for lysosomal targeting. Several lines of evidence indicate that Ang-II-induced ACE2 internalization and lysosomal degradation are mediated by AT 1 R. First, this effect is blocked by the AT 1 R blocker losartan. Second, ACE2 internalization by Ang-II is absent in HEK293T cells, which do not express AT 1 R, but this effect is restored in cells transfected with this receptor. Third, coimmunoprecipitation experiments demonstrated that ACE2 and AT 1 R interact and these interactions are reduced in the presence of Ang-II. These results suggest that, along the endocytic pathway, ACE2 and AT 1 R dissociate, with the former being transported to the lysosomes, whereas the receptor is slowly recycled back to the plasma membrane from early endosomes. Consistent with this idea and in contrast to other G-protein-coupled receptors, AT 1 R expression levels are not always downregulated after chronic exposure to Ang-II in vivo. 9 The role of AT 1 R in the regulation of ACE2 subcellular localization in presence of Ang-II is unique, because its effects cannot be mimicked by AT 2 R or MasR. Recently, similar interactions between G-protein-coupled receptors and the enzyme involved in the degradation of the respective endogenous ligand were reported. Specifically, adenosine deaminase was shown to allosterically bind to adenosine A1 and A2 receptors and modulate receptor signaling. 44 In contrast, in the case of AT 1 R/ACE2 interactions, AT 1 R controls ACE2 expression levels, subcellular localization, and enzymatic activity. Furthermore, internalization of ACE2 Figure 5 . A. Angiotensin II (Ang-II) stimulates angiotensinconverting enzyme type 2 (ACE2) ubiquitination. HEK293T cells were transfected in 10 cm 2 plates with 10 μg ACE2-GFP, 10 μg HA-ubiquitin, and either 10 μg pcDNA3.1 (first lane) or 10 μg Ang-II type 1 receptor (AT 1 R; lanes 2-4). Cells were serum-starved for 24 h and treated with Ang-II (100 nmol/L) for the indicated time periods. Cells were then lysed, and ACE2interacting proteins were pulled down by treatment with a GFP antibody (2 μg/mg). Cell lysates were separated by 10% SDS-PAGE, and ubiquitin levels were revealed by Western blotting using anti-HA antibody. The experiment shown is representative from 3 independent transfections. **P<0.01 B, ACE2 interaction with AT 1 R in HEK293T cells determined by coimmunoprecipitation. Cells were transfected in 10 cm 2 plates with 10 μg ACE2-GFP and 10 μg pcDNA3.1 (lane 1) or 10 μg AT 1 R (lanes 2-4) . Cells were serum-starved for 24 h and treated with Ang-II (100 nmol/L) for the indicated time periods. After lysis, ACE2-interacting proteins were pulled down by treatment with a GFP antibody (2 μg/mg). also supports the concept that Ang-II has intracellular actions independent of activation of plasma membrane receptors. Indeed, along with a functional intracellular renin-angiotensin system, detectable intracellular Ang-II levels ranging from 5 to 20 fmol/g have been reported in several tissues. 45 Whether or not the internalized ACE2 can also act in the endosomes to generate Ang-(1-7) remains to be determined. This unexpected feature of AT 1 R seems important in the regulation of BP at least at the CNS level. Our group 3, 6, 29, 46 and others 8, 47 have shown that brain ACE2 overexpression blunts the central effects of Ang-II. Moreover, the effects of central Ang-II on cardiac sympathetic tone, brain NADPH oxidase, and superoxide dismutase activities are significantly increased in ACE2 knockout mice, 7 although differences in baseline BP levels were only observed in aging mice. In the present study, we found that leupeptin significantly attenuated the hypertensive effects of Ang-II. However, the effects of this protease inhibitor were eliminated in ACE2 knockout mice, indicating that its effects are at least mediated by prevention of ACE2 lysosomal degradation, as also indicated by the finding that leupeptin enhanced ACE2 activity in presence of chronic Ang-II treatment. Although the lack of change in baseline BP for ACE2 knockout mice is difficult to reconcile with a major regulatory role of the enzyme, at least in basal conditions, our data clearly show that ACE2 internalization contributes to Ang-II-mediated hypertension.
Perspective
This study is the first demonstration that central hypertensive effects of Ang-II are at least in part mediated by decreasing ACE2 activity and stimulation of the carboxypeptidase lysosomal degradation through an AT 1 R-dependent mechanism. This feed-forward mechanism, supporting the reduction of ACE2, limits the formation and therefore availability of Ang-(1-7) and enhances the pathological actions of Ang-II. Soluble recombinant ACE2 has been proposed as a new therapeutic approach in cardiovascular diseases and could be used to diminish the circulating levels of Ang-II. Our study indicates that this may have great value during chronic stimulation of AT 1 R because soluble recombinant ACE2 is not associated with the plasma membrane and therefore unlikely to be downregulated. Alternatively, an ACE2 derivative resistant to internalization and degradation may potentially have a therapeutic value. What Is New?
• This study demonstrates that angiotensin-converting enzyme type 2 (ACE2) undergoes an internalization and degradation process on exposure to angiotensin II levels involving ubiquitination of the enzyme and physical interaction with the angiotensin II type 1 receptor.
• Reduction of angiotensin II-mediated hypertension could be achieved by prevention of ACE2 degradation in lysosomes.
What Is Relevant?
• Elevation of angiotensin II levels in hypertension results in reduction of ACE2 compensatory activity. Identification of the mechanisms respon-sible for ACE2 downregulation provides new opportunities for hypertension treatment.
Summary
Elevation of angiotensin II levels leads to ACE2 downregulation via internalization and degradation in lysosomes. 
